FDA calls for more broadly applicable drug development tools

被引：0
|
作者：
不详
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 12期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：907 / 907
页数：1
相关论文
共 50 条
  • [41] The More Things Change: Improvement Patents, Drug Modifications, and the FDA
    Karshtedt, Dmitry
    IOWA LAW REVIEW, 2019, 104 (03) : 1129 - 1222
  • [42] FDA outlines steps for individualized drug development
    Asher Mullard
    Nature Reviews Drug Discovery, 2021, 20 : 91 - 91
  • [43] THE FDA AND FOREIGN DATA - EFFECTS ON DRUG DEVELOPMENT
    WEINTRAUB, M
    HOSPITAL FORMULARY, 1986, 21 (04): : 415 - 415
  • [44] FDA outlines steps for individualized drug development
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (02) : 91 - 91
  • [45] Flexibility in the FDA approach to orphan drug development
    Nina L. Hunter
    Gayatri R. Rao
    Rachel E. Sherman
    Nature Reviews Drug Discovery, 2017, 16 : 737 - 738
  • [46] FDA: Evidentiary Standards for Drug Development and Approval
    Katz R.
    NeuroRX, 2004, 1 (3): : 307 - 316
  • [47] New FDA recommendations to speed drug development
    Shalev M.
    Lab Animal, 2006, 35 (3) : 13 - 13
  • [48] FDA's role in anesthetic drug development
    Landow, L
    Kahn, RC
    Wright, C
    ANESTHESIOLOGY, 1999, 90 (03) : 882 - 889
  • [49] FDA regulatory considerations for oncology drug development
    Moon, Hanlim
    Zang, Dae Young
    Ryu, Min-Hee
    Seo, Yeonsook
    Oh, Bitna
    Hwang, Sunjin
    Farrand, Lee
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [50] Flexibility in the FDA approach to orphan drug development
    Hunter, Nina L.
    Rao, Gayatri R.
    Sherman, Rachel E.
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (11) : 737 - 738
12345